QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL

QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL

Show other versions (1)

Aim. To study changes in quality of life (QoL) in patients with atrial fibrillation (AF) treated with warfarin after leaving the international clinical trial. Material and Methods. Patients with AF who were managed at cardiology department of the University Hospital participated in the study. Patien...

Full description

Bibliographic Details
Main Authors:	E. L. Artanova, L. E. Kon'shina, I. M. Sokolov, Y. G. Shvarts
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	atrial fibrillation quality of life clinical trials warfarin
Online Access:	https://www.rpcardio.com/jour/article/view/532

Similar Items

Control of anticoagulant therapy and quality of life of patients with atrial fibrillation (review)
by: Shvarts Y.G., et al.
Published: (2012-06-01)

SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS
by: E. L. Artanova, et al.
Published: (2016-01-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Hypercoagulability in patients with atrial fibrillation and associated obesity: a way to hemorrhage or thromboembolia?
by: Yu. V. Kovbasniuk, et al.
Published: (2017-10-01)

QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL
by: E. L. Artanova, et al.
Published: (2015-12-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2016-01-01)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
by: Carolina eMalta Hansen, et al.
Published: (2012-06-01)

Cognitive impairment in patients with atrial fibrillation: What is the importance of anticoagulant therapy?
by: Giovanni Capobianco
Published: (2018-06-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)–A report on periprocedural oral anticoagulants
by: Yuji Murakawa, MD, et al.
Published: (2015-02-01)

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Clinical Profile of Atrial Fibrillation in Tertiary Hospital in Central Nepal
by: Sachin Dhungel, et al.
Published: (2017-09-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019-09-01)

New possibilities in the prevention of stroke in atrial fibrillation
by: Vladimir Anatolyevich Parfenov, et al.
Published: (2012-03-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

Outcomes and direct treatment costs with novel oral anticoagulants compared to clinic-monitored warfarin for stroke prevention in atrial fibrillation
by: Hulvershorn, Sarah Elizabeth
Published: (2014)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Modern warfarin- dosing algorithms in patients with atrial fibrillation
by: M. Yu. Kolesnyk, et al.
Published: (2015-12-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
by: Fernando Pivatto Júnior, et al.
Published: (2015-07-01)

Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
by: Fernando Pivatto Júnior, et al.
Published: (2015-07-01)

Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
by: Mahito Ozawa, MD, et al.
Published: (2009-01-01)

Clinical practices of the management of nonvalvular atrial fibrillation and outcome of treatment: A representative prospective survey in tertiary healthcare centers across Turkey
by: Bülent Özin, et al.
Published: (2018-03-01)

The use of warfarin in veterans with atrial fibrillation
by: Rosenbeck Karen, et al.
Published: (2004-10-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
by: Amal K Sulieman
Published: (2016-01-01)

What clinical trials of ablation for atrial fibrillation tell us – and what they do not
by: Ram Amuthan, MD, et al.
Published: (2021-04-01)

Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable
by: D. A. Napalkov, et al.
Published: (2018-11-01)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
by: Gabriela Lopes Martins, et al.
Published: (2020-07-01)

Outpatient Management of Oral Anticoagulation Therapy in Patients with Nonvalvular Atrial Fibrillation
by: Aida Kulo, et al.
Published: (2009-11-01)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
by: Yuji Murakawa, MD, et al.
Published: (2017-06-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_9hmoafio1rrlentmsqph65uum1